Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US House Drug Pricing Hearings Start Slow As Pharma Execs Dodge Some Punches

Executive Summary

Bristol Myers Squibb CEO Giovanni Caforio, former Celgene CEO Mark Alles and Teva CEO Kare Schultz fielded roughly four hours of questioning at an oversight hearing on pricing practices for Revlimid and Copaxone.

You may also be interested in...



Pharma Catches A Break As Democrats Stumble In Rollout Of Pricing Investigation

House Oversight Committee plans to grill more companies on pricing later this year, but rushed rollout of reports from a long-running investigation, combined with competing higher profile news events, seemed to dampen the blow of the latest drug pricing scrutiny. Democrats failed to offer any new, unified solutions for their grievances with industry, while Republicans largely rushed to pharma’s defense.

Amgen Shadow Pricing Of Enbrel Under Scrutiny At US House Hearing

Amgen CEO Bradway told Congress the biggest driver of list pricing for Enbrel has been the need to match the price of AbbVie's Humira to secure formulary access.

Revlimid And Copaxone Pricing: Five Not-So-Revealing Revelations From The House Reports

Investigative reports from the House Oversight and Reform Committee recount well-known records of significant price increases for the drugs, the lack of pricing restraints in the US relative to markets abroad, tactics used to protect the drugs from generic competition and the 'return on investment' from manufacturer assistance programs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel